KR20250065423A - 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도 - Google Patents

항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도 Download PDF

Info

Publication number
KR20250065423A
KR20250065423A KR1020257013411A KR20257013411A KR20250065423A KR 20250065423 A KR20250065423 A KR 20250065423A KR 1020257013411 A KR1020257013411 A KR 1020257013411A KR 20257013411 A KR20257013411 A KR 20257013411A KR 20250065423 A KR20250065423 A KR 20250065423A
Authority
KR
South Korea
Prior art keywords
seq
cmklr1
ser
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257013411A
Other languages
English (en)
Korean (ko)
Inventor
니꼴라 뿌와리에
꺄롤린 마리
베르나르 방오브
바네싸 고티에
샤를렌느 트릴요
마끄 뒤부르도
Original Assignee
오제 이뮈노테라프틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오제 이뮈노테라프틱스 filed Critical 오제 이뮈노테라프틱스
Publication of KR20250065423A publication Critical patent/KR20250065423A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020257013411A 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도 Pending KR20250065423A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18305395 2018-04-03
EP18305395.8 2018-04-03
PCT/EP2019/058358 WO2019193029A1 (en) 2018-04-03 2019-04-03 Anti-chemokin like receptor 1 antibodies and their therapeutic applications
KR1020207031788A KR102802041B1 (ko) 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031788A Division KR102802041B1 (ko) 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도

Publications (1)

Publication Number Publication Date
KR20250065423A true KR20250065423A (ko) 2025-05-12

Family

ID=62046804

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207031788A Active KR102802041B1 (ko) 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도
KR1020257013411A Pending KR20250065423A (ko) 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207031788A Active KR102802041B1 (ko) 2018-04-03 2019-04-03 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도

Country Status (11)

Country Link
US (2) US20210147558A1 (enExample)
EP (2) EP4656247A2 (enExample)
JP (2) JP2021520210A (enExample)
KR (2) KR102802041B1 (enExample)
CN (2) CN112218894A (enExample)
AU (1) AU2019247068A1 (enExample)
BR (1) BR112020020118A2 (enExample)
CA (1) CA3102607A1 (enExample)
IL (2) IL277701A (enExample)
MA (1) MA52174A (enExample)
WO (1) WO2019193029A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) * 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
EP3804754A1 (en) * 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
US20240084019A1 (en) * 2019-10-09 2024-03-14 Ose Immunotherapeutics Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
EP4279142A4 (en) 2021-01-15 2024-12-04 Reel Tech Co., Ltd. PORTABLE EMERGENCY ESCAPE DEVICE
US11986512B2 (en) 2021-10-26 2024-05-21 Thetis Phamaceuticals LLC Compositions and methods for cancer therapy
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
US8038992B2 (en) * 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
US9195150B2 (en) * 2012-02-06 2015-11-24 Asml Netherlands B.V. Lithographic apparatus comprising a support for holding an object, and a support for use therein
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Also Published As

Publication number Publication date
US20210147558A1 (en) 2021-05-20
JP2024105648A (ja) 2024-08-06
IL277701A (en) 2020-11-30
CN120484119A (zh) 2025-08-15
WO2019193029A1 (en) 2019-10-10
AU2019247068A1 (en) 2020-10-22
IL321209A (en) 2025-07-01
MA52174A (fr) 2021-02-17
KR102802041B1 (ko) 2025-04-30
KR20210006359A (ko) 2021-01-18
BR112020020118A2 (pt) 2021-02-23
US20240400698A1 (en) 2024-12-05
EP3774899A1 (en) 2021-02-17
CN112218894A (zh) 2021-01-12
EP4656247A2 (en) 2025-12-03
JP2021520210A (ja) 2021-08-19
CA3102607A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
KR102802041B1 (ko) 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도
KR101643005B1 (ko) 항ｎｒ１０ 항체 및 그의 이용
KR101690334B1 (ko) 개량된 항체분자
KR102452349B1 (ko) Ceacam1에 대한 인간화 항체
KR20180133482A (ko) 항-tim-3 항체 및 조성물
KR20140091736A (ko) 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
KR20100091245A (ko) 항ｎｒ１０ 항체 및 그의 이용
KR20150082367A (ko) 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
KR102478986B1 (ko) 암 치료용 항-ck8 항체
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
KR20250160366A (ko) 항-il-27 항체 및 이의 용도
KR20210068065A (ko) 안타고니스트
TW201028165A (en) Anti-NR10 antibody, and use thereof
JP2022552490A (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
TW202313110A (zh) 癌症之治療
CN112175087B (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
AU2022290831B2 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof
AU2021403263B2 (en) Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof
KR20220151522A (ko) Tie2 작용제 항체 및 이의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250423

Application number text: 1020207031788

Filing date: 20201103

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250520

Comment text: Request for Examination of Application